Unveiling the nephrotoxic profile of BCR-ABL tyrosine kinase inhibitors: A real-world experience in Africa.
Zekarias Seifu AyalewGebeyehu Tessema AzibteFisihatsion TadesseBiruk Abate LegesseZerubabel Getahun KifluMahlet Tsige WeldeamanuelKibrekidusan Aynekulu TsigeBereket Abraha MollaAddisu Melkie EjiguPublished in: EJHaem (2024)
While this study found that BCR-ABL TKIs can lead to a decline in eGFR, AKI, and CKD, it also demonstrated that they were relatively safer in our study population.